Pharmacologic and biochemical profiles of new venous antithrombotic β-D-xyloside derivatives: Potential antiathero/thrombotic drugs

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 3, 1996, Pages 247-254

  Martin, Niall B ^a,b   Masson, Philippe ^a   Sepulchre, Christiane ^a   Theveniaux, Jocelyne ^a   Millet, Jean ^a   Bellamy, Francois ^a  

^a Laboratoires Fournier   (France)

^b Laboratoires Fournier SA   (France)

Author keywords

Galactosyltransferase 1; Glycosaminoglycans; Heparin cofactor II; Thioxylosides; Venous antithrombotic

Indexed keywords

ANTICOAGULANT AGENT; BECIPARCIL; DERMATAN SULFATE; GALACTOSYLTRANSFERASE; GLYCOSAMINOGLYCAN; HEPARIN COFACTOR II; ILIPARCIL; LF 040212; LF 050030; LF 090055; NAROPARCIL; UNCLASSIFIED DRUG; XYLAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG SCREENING; GLYCOSAMINOGLYCAN METABOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; RABBIT; RAT; VEIN THROMBOSIS;

EID: 0029977764     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999015     Document Type: Article

References (43)

1. Morris GK: Prevention of venous thromboembolism: a survey of methods used in general and orthopaedic surgery. Lancet 1:572-574, 1980.
2. Verstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparin. Drugs 40:498-530, 1990.
3. Mant MJ, BD O'Brien, KL Thong, GW Hammond, RV Birtwhistle, MG Grace: Haemorrhagic complications of heparin therapy. Lancet 1:1133-1134, 1977.
4. Fagher B, B Lundh: Heparin treatment of deep vein thrombosis. Effects and complications after continuous or intermittent heparin administration. Acta Med Scand 210:357-360, 1981.
5. Kelton JG: Heparin induced thrombocytopenia. Haemostasis 16:173-186, 1986.
6. Fareed J, D Hoppensteadt, JM Walenga, R Pifarre: An overview of current anticoagulant and antithrombotic drugs. In: Pifarre R (ed): Anticoagulant Hemostasis and Blood Preservation in Cardiovascular Surgery. Hanley and Belfus, Philadelphia, 1993, pp 111-129.
7. Agnelli G, B Cosmi, P Di Filippo, V Ranucci, F Veschi, M Longetti, C Renga, F Barzi, F Gianese, L Lupatteli, E Rinonapoli, GG Nenci: A randomized double-blind, placebo controlled trial of dermatan sulfate in prevention of deep vein thrombosis in hip fracture. Thromb Haemostas 67:203-208, 1992.
8. Ten Cate JW: Prevention of deep vein thrombosis following total hip replacement surgery by Orgaran. Haemostasis 22:109-111, 1992.
9. Galligani L, J Hopwood, NB Schwartz, A Dorfman: Stimulation of synthesis of free chondroitin sulfate chains by β-D-xylosides in cultured cells. J Biol Chem 250:5400-5406, 1975.
10. Tanaka A, A Morikawa, Y Saito, S Tamura, T Nakamura, K Takagaki, M Endo: Simple measurement of glycosaminoglycan produced by cultured fibroblasts using 4-methylumbelliferyl β-D-xyloside. J Biochem Biophys Methods 26:309-316, 1993.
11. Samreth S, V Barberousse, F Bellamy, D Horton, P Masson, J Millet, P Renaut, C Sepulchre, J Theveniaux: Thioxyloside derivatives, a novel oral venous antithrombotic. Actual Chim Ther 21:23-33, 1994.
12. Millet J, J Theveniaux, NL Brown: The venous antithrombotic effect of LF 1351 in the rat following oral administration. Thromb Haemostas 67:176-179, 1992.
13. Samreth S, V Barberousse, F Bellamy, D Horton, P Masson, J Millet, P Renaut, C Sepulchre, J Theveniaux: Synthesis and structure-activity relationships of glycosylated and thioglycosylated derivatives of benzophenone, benzhydrol, benzhydril as oral antithrombotic agents. In Claassen V (ed): Trends in Receptor Research, vol 20. Elsevier Science Publishers B.V., Amsterdam, 1993, pp 41-59.
14. Wessier S, M Reimer, M Sheps: Biologic assay of a thrombosis inducing activity in human serum. J Appl Physiol 14:943-946, 1959.
15. Fareed J, JM Walenga, A Kumar, A Rock: A modified stasis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemostas 11:155-175, 1985.
16. Millet J, J Theveniaux, NL Brown: The venous antithrombotic profile of Naroparcil in the rabbit. Thromb Haemostas 72:874-879, 1994.
17. Millet J, J Theveniaux, M Vaillot, P Chicaud, NL Brown: Venous antithrombotic profile of LF 5.0030 following oral administration to rats. (Abst.) Thromb Haemostas 69:672, 1993.
18. Millet J, J Theveniaux, M Pascal: A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelial alterations. Thromb Res 45:123-133, 1987.
19. Reyers I, L Mussoni, MB Donati, G de Gaetano: Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 18:669-674, 1980.
20. Dupouy D, P Sie, F Dol, B Boneu: A simple method to measure dermatan sulfate at sub-microgram concentrations in plasma. Thromb Haemostas 60:236-239, 1988.
21. Carter CJ, JG Kelton, J Hirsh, AV Santos, M Gent: The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59:1239-1245, 1982.
22. Okayama M, K Kimata, S Suzuki: The influence of p-nitrophenyl-β-D-xyloside on the synthesis of proteochondroitin sulfate by slices of embryonic chick cartilage. J Biochem 74:1069-1073, 1973.
23. Robinson HC, MJ Brett, PJ Tralaggan, DA Lowther, M Okayama: The effect of D-xylose, β-D-xylosides and β-D-galactosides on chondroitin sulphate biosynthesis in embryonic chicken cartilage. Biochem J 148:25-34, 1975.
24. Robinson JA, HC Robinson: Control of chondroitin sulphate biosynthesis. β-D-xylopyranosides as substrates for UDP-galactose: D-xylose transferase from embryonic-chicken cartilage. Biochem J 194:839-846, 1981.
25. Kearns AE, SC Campbell, J Westley, NB Schwartz: Initiation of chondroitin sulfate biosynthesis: a kinetic analysis of UDP-D-xylose:core protein β-D-xylosyltransferase. Biochemistry 30: 7477-7483, 1991.
26. Stevens RL, KF Austen: Effect of p-nitrophenyl-β-D-xyloside on proteoglycan and glycosaminoglycan biosynthesis in rat serosal mast cell cultures. J Biol Chem 257:253-259, 1982.
27. Stevens RL, E Razin, KF Austen, A Hein, JP Caulfield, N Seno, K Schmid, F Akiyama: Synthesis of chondroitin sulfate E onto p-nitrophenyl-β-D-xyloside and its localization to the secretory granules of rat serosal mast cells and mouse bone marrow-derived mast cells. J Biol Chem 258:5977-5984, 1983.
28. Murray E, T Scott-Burden, P Ferguson, W Gevers: Increased sulphation level and altered composition of glycosaminoglycans synthesized by cultured smooth muscle cells in the presence of β-D-xylosides. Biochim Biophys Acta 763:299-308, 1983.
29. Robinson J, D Gospodarowicz: Effect of p-nitrophenyl-β-D-xyloside on proteoglycan synthesis and extracellular matrix formation by bovine corneal endothelial cell cultures. J Biol Chem 259: 3818-3824, 1984.
30. Gordon PB, DR Zanger, VB Hatcher: Extracellular matrix proteoglycans and cell-substratum adhesion of human endothelial cells: the effect of methyl-β-D-xylopyranoside. Carbohydr Res 151:121-134, 1986.
31. Sobue M, H Habuchi, K Ito, H Yonekura, K Oguri, K Sakurai, S Kamohara, Y Ueno, R Noyori, S Suzuki: β-D-xylosicles and their analogues as artificial initiators of glycosaminoglycan chain synthesis. Biochem J 41:591-601, 1987.
32. Kolset SO, K Sakurai, I Ivhed, A Overvatn, S Suzuki: The effect of β-D-xylosides on the proliferation and proteoglycan biosynthesis of monoblastic U-937 cells. Biochem J 265:637-645, 1990.
33. Tagaki K, T Nakamura, A Kon, S Tamura, M Endo: Characterization of β-D-xyloside-induced glycosaminoglycans and oligosaccharides in cultured human skin fibroblasts. J Biochem 109:514-519, 1991.
34. Cöster L, J Hernnäs, A Malmström: Biosynthesis of dermatan sulphate proteoglycans. The effect of β-D-xyloside on the polymer-modification process in fibroblast cultures. Biochem J 276: 533-539, 1991.
35. Masson PJ, D Coup, J Millet, NL Brown: The effect of the β-D-xyloside Naroparcil on circulating plasma glycosaminoglycans: An explanation for its known antithrombotic activity in the rabbit. J Biol Chem 270:2662-2668, 1995.
36. Linhardt RJ, D Loganathan: Heparin, heparinoids and heparin oligosaccharides: structure and biological activities. In Gebellein G (ed): Biometric Polymers. Plenum Press, New York, 1990, pp 135-178.
37. Fernandez F, J van Ryn, F Ofosu, J Hirsh, MR Buchanan: The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 64:309-317, 1986.
38. Currier JW, TK Pow, CH Haudenschild, AC Minihan, DP Faxon: Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol 17:118B-125B, 1991.
39. Matsushima T, Y Nakashima, M Sugano, H Tasaki, A Kuroiwa, O Koida: Suppression of atherogenesis in hypercholesterolemic rabbits by chondroitin-6-sulphate. Artery 14:316-337, 1987.
40. Steg PG, M Ziol, O Tahlil, C Robert, P Masson, D Pruneau, P Bruneval, P Belichard: Reduction of intimai hyperplasia by Naroparcil a 4-methylumbelliferyl β-D-xyloside analogue, after arterial injury in the hypercholesterolemic rabbit. Circ Res 77: 919-926, 1995.
41. Hamati HF, EL Britton, DJ Carey: Inhibition of proteoglycan synthesis alters extracellular matrix deposition, proliferation, and cytoskeletal organisation of rat aortic smooth muscle cells in culture. J Cell Biol 108:2495-2505, 1989.
42. Wong YC, L Chang: Effects of p-nitrophenyl-β-D-xylopyranoside (β-D-xyloside) on the androgen-induced growth of the lateral prostate of the prepubertally castrated guinea pig. Prostate 23: 37-59, 1993.
43. Hascall VC: Proteoglycans: structure and function. In: Ginsburg V, P Robbins (ed): Biology of Carbohydrates, vol. 1. John Wiley & Sons, New York, 1981, pp 1-49.